Cerus Corporation to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Cerus Corporation (CERS) announced its participation in two upcoming investor conferences. CEO William ‘Obi’ Greenman will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 14-15. He, along with CFO Kevin Green, will partake in a fireside chat at Cowen’s 43rd Annual Health Care Conference on March 8 at 1:30 PM EST, with a live webcast available at this link. Cerus, based in Concord, California, is focused on securing the global blood supply, offering the only pathogen-reduction system for platelets and plasma with CE mark and FDA approval.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that the Company will participate in two upcoming investor conferences.

• William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to be in attendance at BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 14^th and Wednesday, February 15^th.
• William ‘Obi’ Greenman and Kevin Green, Cerus’ vice president and chief financial officer, are scheduled to participate in a fireside chat at Cowen’s 43^rd Annual Health Care Conference on Wednesday, March 8^th at 1:30 PM EST. A live webcast of the fireside chat will be available at https://wsw.com/webcast/cowen132/cers/2009322. A replay will be available after the event.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230210005114/en/

Joel Trujillo – Senior Director, Investor Relations

Cerus Corporation

925-288-6137

Source: Cerus Corporation

FAQ

What events is Cerus Corporation participating in for February and March 2023?

Cerus Corporation will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 14-15, 2023, and a fireside chat at Cowen’s 43rd Annual Health Care Conference on March 8, 2023.

When is the Cowen Health Care Conference where Cerus will participate?

The Cowen Health Care Conference is scheduled for March 8, 2023, at 1:30 PM EST.

How can I watch the Cerus fireside chat at the Cowen Conference?

The fireside chat can be watched live via webcast at this link: https://wsw.com/webcast/cowen132/cers/2009322.

Where is Cerus Corporation headquartered?

Cerus Corporation is headquartered in Concord, California.

What is the core mission of Cerus Corporation?

Cerus Corporation is dedicated to safeguarding the world’s blood supply and aims to be the leading global blood products company.